The Efficacy, Safety, and Persistence of Therapy after Non-Medical Switching from an Originator Adalimumab in Inflammatory Bowel Disease: Real-Life Experience from Two Tertiary Centres

• প্রধান লেখক: Teodora Spataru (লেখক), Remus Popescu (লেখক), Monica State (লেখক), Mihai Pahomeanu (লেখক), Bogdan Mateescu (লেখক), Lucian Negreanu (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: MDPI AG, 2024-10-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

During the last two decades, an increased number of molecules with multiple mechanisms of action have been approved for the treatment of inflammatory bowel disease (IBD), with a substantial increase in the costs related to therapy, which has become a concern for payers, regulators, and healthcare pr...